Kiniksa Pharmaceuticals International, plc
KNSA
Rankning i aktier
#2868
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Aktiekurs
$83.13
Senast synkroniserad: 2026-10-20
Marknadsvärde
$6.49B
Förändring (1 dag)
4.59%
Förändring (1 år)
113.97%
Land
GB
Handel Kiniksa Pharmaceuticals International, plc (KNSA)
Kategori
Healthcare
Historik för aktiesplit för Kiniksa Pharmaceuticals International, plc (KNSA)
Aktien Kiniksa Pharmaceuticals International, plc (symbol: KNSA) har genomgått totalt 0 aktiesplitar.
Den senaste spliten skedde den Oct 21, 2026.
En KNSA-aktie köpt före Oct 21, 2026 motsvarar nu 0 KNSA-aktier.
Den senaste spliten skedde den Oct 21, 2026.
En KNSA-aktie köpt före Oct 21, 2026 motsvarar nu 0 KNSA-aktier.
Lista över aktiesplitar
| År | Split | Multipel | Kumulativ multipel |
|---|---|---|---|
| Inte tillräckligt med data för de angivna datumen. | |||
Aktiesplitar för liknande företag eller konkurrenter
| Företag | Antal aktiesplitar | Kumulativ multipel | Land |
|---|---|---|---|
| 0 | - |
US
|
|
| 0 | - |
SE
|
|
| 0 | - |
FR
|
|
| 0 | - |
IT
|
|
| 0 | - |
US
|
